Shanxi Zhendong Pharmaceutical Co.,Ltd (300158.SZ)
CNY 4.78
(-0.21%)
CNY 4.78
(-0.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.03 Billion CNY | -21.94% |
| 2022 | 1.32 Billion CNY | -34.89% |
| 2021 | 2.03 Billion CNY | 3.5% |
| 2020 | 1.97 Billion CNY | 33.64% |
| 2019 | 1.47 Billion CNY | -20.32% |
| 2018 | 1.85 Billion CNY | -10.0% |
| 2017 | 2.05 Billion CNY | 28.24% |
| 2016 | 1.6 Billion CNY | -21.42% |
| 2015 | 2.04 Billion CNY | 129.67% |
| 2014 | 888.23 Million CNY | 5.91% |
| 2013 | 838.63 Million CNY | 22.56% |
| 2012 | 684.26 Million CNY | 72.18% |
| 2011 | 397.4 Million CNY | 2.13% |
| 2010 | 389.12 Million CNY | 37.08% |
| 2009 | 283.87 Million CNY | 23.43% |
| 2008 | 229.97 Million CNY | -20.77% |
| 2007 | 290.27 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 902.25 Million CNY | -12.94% |
| 2024 Q2 | 853.38 Million CNY | -5.42% |
| 2024 Q3 | 801.65 Million CNY | -6.06% |
| 2023 FY | 1.03 Billion CNY | -21.94% |
| 2023 Q1 | 1.2 Billion CNY | -8.96% |
| 2023 Q4 | 1.03 Billion CNY | 8.76% |
| 2023 Q2 | 996.83 Million CNY | -17.53% |
| 2023 Q3 | 952.93 Million CNY | -4.4% |
| 2022 Q3 | 1.65 Billion CNY | -14.78% |
| 2022 Q2 | 1.94 Billion CNY | -4.94% |
| 2022 Q1 | 2.04 Billion CNY | 0.13% |
| 2022 FY | 1.32 Billion CNY | -34.89% |
| 2022 Q4 | 1.32 Billion CNY | -19.73% |
| 2021 Q1 | 1.86 Billion CNY | -5.22% |
| 2021 Q3 | 1.93 Billion CNY | 8.04% |
| 2021 FY | 2.03 Billion CNY | 3.5% |
| 2021 Q4 | 2.03 Billion CNY | 5.41% |
| 2021 Q2 | 1.79 Billion CNY | -4.11% |
| 2020 Q3 | 2 Billion CNY | 13.42% |
| 2020 Q1 | 1.73 Billion CNY | 17.78% |
| 2020 FY | 1.97 Billion CNY | 33.64% |
| 2020 Q2 | 1.76 Billion CNY | 1.78% |
| 2020 Q4 | 1.97 Billion CNY | -1.71% |
| 2019 Q1 | 1.93 Billion CNY | 4.7% |
| 2019 FY | 1.47 Billion CNY | -20.32% |
| 2019 Q4 | 1.47 Billion CNY | -4.97% |
| 2019 Q3 | 1.55 Billion CNY | -15.85% |
| 2019 Q2 | 1.84 Billion CNY | -4.84% |
| 2018 Q1 | 1.83 Billion CNY | -10.89% |
| 2018 Q3 | 1.8 Billion CNY | -6.7% |
| 2018 FY | 1.85 Billion CNY | -10.0% |
| 2018 Q2 | 1.93 Billion CNY | 5.51% |
| 2018 Q4 | 1.85 Billion CNY | 2.6% |
| 2017 Q3 | 1.65 Billion CNY | -4.61% |
| 2017 Q2 | 1.73 Billion CNY | 4.85% |
| 2017 Q1 | 1.65 Billion CNY | 3.2% |
| 2017 Q4 | 2.05 Billion CNY | 24.25% |
| 2017 FY | 2.05 Billion CNY | 28.24% |
| 2016 FY | 1.6 Billion CNY | -21.42% |
| 2016 Q3 | 1.8 Billion CNY | -24.7% |
| 2016 Q4 | 1.6 Billion CNY | -11.12% |
| 2016 Q1 | 2.13 Billion CNY | 4.55% |
| 2016 Q2 | 2.39 Billion CNY | 12.3% |
| 2015 Q2 | 1.17 Billion CNY | 29.97% |
| 2015 Q4 | 2.04 Billion CNY | 63.58% |
| 2015 FY | 2.04 Billion CNY | 129.67% |
| 2015 Q1 | 901.7 Million CNY | 1.52% |
| 2015 Q3 | 1.24 Billion CNY | 6.42% |
| 2014 Q1 | 772.03 Million CNY | -7.94% |
| 2014 FY | 888.23 Million CNY | 5.91% |
| 2014 Q4 | 888.23 Million CNY | -7.31% |
| 2014 Q3 | 958.28 Million CNY | 3.06% |
| 2014 Q2 | 929.86 Million CNY | 20.44% |
| 2013 Q2 | 761.38 Million CNY | -1.93% |
| 2013 Q4 | 838.63 Million CNY | 11.3% |
| 2013 Q3 | 753.48 Million CNY | -1.04% |
| 2013 Q1 | 776.33 Million CNY | 13.46% |
| 2013 FY | 838.63 Million CNY | 22.56% |
| 2012 Q3 | 608.27 Million CNY | 6.73% |
| 2012 FY | 684.26 Million CNY | 72.18% |
| 2012 Q1 | 651.85 Million CNY | 64.03% |
| 2012 Q2 | 569.93 Million CNY | -12.57% |
| 2012 Q4 | 684.26 Million CNY | 12.49% |
| 2011 Q3 | 511.93 Million CNY | 90.98% |
| 2011 FY | 397.4 Million CNY | 2.13% |
| 2011 Q1 | 263.57 Million CNY | -32.27% |
| 2011 Q2 | 268.06 Million CNY | 1.7% |
| 2011 Q4 | 397.4 Million CNY | -22.37% |
| 2010 Q2 | 333.41 Million CNY | 0.0% |
| 2010 Q4 | 389.12 Million CNY | 2.52% |
| 2010 FY | 389.12 Million CNY | 37.08% |
| 2010 Q3 | 379.56 Million CNY | 13.84% |
| 2009 Q4 | 283.87 Million CNY | 0.0% |
| 2009 FY | 283.87 Million CNY | 23.43% |
| 2008 FY | 229.97 Million CNY | -20.77% |
| 2007 FY | 290.27 Million CNY | 0.0% |